Please login to the form below
bempedoic acid
This page shows the latest bempedoic acid news and features for those working in and with pharma, biotech and healthcare.
Esperion’s heart drug shown to reduce risk of major adverse cardiovascular events
The phase 3 CLEAR trial was designed to evaluate whether treatment with Nexletol (bempedoic acid) could reduce the risk of cardiovascular events in patients who are at high risk for cardiovascular
Latest news
-
Esperion gets FDA thumbs up for cholesterol drug Nexletol
Bempedoic acid is described as a first-in-class ATP citrate lyase (ACL) inhibitor that inhibits cholesterol synthesis in the liver. ... The company has also filed bempedoic acid in Europe, as well as a combination pill with ezetimibe, filed with both the
-
Dupixent helps put Sanofi back on growth track
US. However, both these drugs are facing the threat of competition from new oral therapies such as Esperion’s bempedoic acid, which could be filed for approval in early 2019, and
-
Esperion craters as deaths mar atherosclerosis drug study
Esperion has seen almost a fifth of the value wiped off its shares as a phase III trial of its atherosclerosis candidate bempedoic acid revealed a three-fold increase in deaths ... The pivotal trial, which was comparing bempedoic acid to placebo given on
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Reaching patients and HCPs during the pandemic
Esperion planned to launch its lipid-lowering agent, Nexletol (bempedoic acid), in March 2020 before releasing the combination therapy, Nexlizet (bempedoic acid/ezetimibe), in July.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
